請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70471
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳俊任(Chun-Jen Chen) | |
dc.contributor.author | Yang-Chia Lin | en |
dc.contributor.author | 林揚家 | zh_TW |
dc.date.accessioned | 2021-06-17T04:28:55Z | - |
dc.date.available | 2018-08-16 | |
dc.date.copyright | 2018-08-16 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-13 | |
dc.identifier.citation | 1. Boh, B., et al., Ganoderma lucidum and its pharmaceutically active compounds, in Biotechnol Annu Rev, M.R. El-Gewely, Editor. 2007, Elsevier. p. 265-301.
2. Bhagwan, S.S., et al., Ganoderma lucidum: A Potent Pharmacological Macrofungus. Curr Pharm Biotechnol, 2009. 10(8): p. 717-742. 3. Sasaki, T., et al., Antitumor polysaccharides from some polyporaceae, Ganoderma applanatum (Pers.) Pat and Phellinus linteus (Berk. et Curt) Aoshima. Chem Pharm Bull (Tokyo), 1971. 19(4): p. 821-6. 4. Li, L.-F., et al., Comprehensive comparison of polysaccharides from Ganoderma lucidum and G. sinense: chemical, antitumor, immunomodulating and gut-microbiota modulatory properties. Sci. Rep, 2018. 8(1): p. 6172. 5. Zeng, Q., et al., Ganoderma lucidum polysaccharides protect fibroblasts against UVB-induced photoaging. Mol Med Rep, 2017. 15(1): p. 111-116. 6. Sun, L.-X., et al., The improvement of M1 polarization in macrophages by glycopeptide derived from Ganoderma lucidum. Immunol Res, 2017. 65(3): p. 658-665. 7. Wang, H., et al., Polysaccharide purified from Ganoderma atrum induced activation and maturation of murine myeloid-derived dendritic cells. Food Chem Toxicol, 2017. 108: p. 478-485. 8. Liu, Z., et al., Ganoderma lucidum polysaccharides encapsulated in liposome as an adjuvant to promote Th1-bias immune response. Carbohydr Polym, 2016. 142: p. 141-148. 9. Wang, C.-L., et al., Activation of antitumor immune responses by Ganoderma formosanum polysaccharides in tumor-bearing mice. Appl Microbiol Biotechnol, 2014. 98(22): p. 9389-9398. 10. Pi, C.-C., et al., Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo. Vaccine, 2014. 32(3): p. 401-408. 11. Wang, C.L., et al., Extracellular polysaccharides produced by Ganoderma formosanum stimulate macrophage activation via multiple pattern-recognition receptors. BMC Complement Altern Med, 2012. 12: p. 119. 12. Wang, C.-L., et al., Polysaccharides purified from the submerged culture of Ganoderma formosanum stimulate macrophage activation and protect mice against Listeria monocytogenes infection. Biotechnol Lett, 2011. 33(11): p. 2271. 13. Oberic, L., et al., Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. Radiat Oncol, 2011. 6: p. 124. 14. Pinedo, H.M. and G.F. Peters, Fluorouracil: biochemistry and pharmacology. J Clin Oncol, 1988. 6(10): p. 1653-1664. 15. Longley, D.B., D.P. Harkin, and P.G. Johnston, 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 2003. 3: p. 330. 16. Milano, G. and M.C. Etienne, Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anticancer Res, 1994. 14(6a): p. 2295-7. 17. PAPANASTASOPOULOS, P. and J. STEBBING, Molecular Basis of 5-Fluorouracil-related Toxicity: Lessons from Clinical Practice. Anticancer Res, 2014. 34(4): p. 1531-1535. 18. Lizée, G., et al., Harnessing the Power of the Immune System to Target Cancer. Annu Rev Med, 2013. 64(1): p. 71-90. 19. Dougan, M. and G. Dranoff, Immune Therapy for Cancer. Annu Rev Immunol, 2009. 27(1): p. 83-117. 20. Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nat Rev Cancer, 2015. 15(6): p. 361-70. 21. Melero, I., et al., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer, 2015. 15: p. 457. 22. Derer, A., et al., Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother, 2016. 65(7): p. 779-786. 23. Ritz, U., et al., Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol, 2001. 19(6): p. 1211-20. 24. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 2004. 4: p. 11. 25. Kessenbrock, K., V. Plaks, and Z. Werb, Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell, 2010. 141(1): p. 52-67. 26. Yang, L., et al., Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 2004. 6(4): p. 409-421. 27. Sinha, P., et al., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol, 2007. 179(2): p. 977-83. 28. Hestdal, K., et al., Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol, 1991. 147(1): p. 22-8. 29. Youn, J.I., et al., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol, 2008. 181(8): p. 5791-802. 30. Noonan, K.A., et al., Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res, 2014. 2(8): p. 725-31. 31. Crittenden, M.R., et al., Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice. Radiat Res, 2014. 182(2): p. 182-90. 32. Srivastava, M.K., et al., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res, 2010. 70(1): p. 68-77. 33. Huang, B., et al., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host Cancer Res, 2006. 66(2): p. 1123-1131. 34. Serafini, P., et al., Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res, 2008. 68(13): p. 5439-49. 35. Martinez, F.O. and S. Gordon, The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep, 2014. 6. 36. Sica, A. and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas. J Clin Invest, 2012. 122(3): p. 787-95. 37. Mosser, D.M. and J.P. Edwards, Exploring the full spectrum of macrophage activation. Nat Rev Immunol, 2008. 8: p. 958. 38. Qian, B.Z. and J.W. Pollard, Macrophage diversity enhances tumor progression and metastasis. Cell, 2010. 141(1): p. 39-51. 39. Ding, L., et al., IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol, 1993. 151(3): p. 1224-34. 40. Kuang, D.M., et al., Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med, 2009. 206(6): p. 1327-37. 41. Pollard, J.W., Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 2004. 4(1): p. 71-8. 42. Adeegbe, D. and H. Nishikawa, Natural and Induced T Regulatory Cells in Cancer. Front Immunol, 2013. 4(190). 43. Liston, A. and D.H. Gray, Homeostatic control of regulatory T cell diversity. Nat Rev Immunol, 2014. 14(3): p. 154-65. 44. Liu, C., C.J. Workman, and D.A. Vignali, Targeting regulatory T cells in tumors. Febs j, 2016. 283(14): p. 2731-48. 45. Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004. 10(9): p. 942-9. 46. Plitas, G., et al., Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity, 2016. 45(5): p. 1122-1134. 47. Curiel, T.J., Regulatory T cells and treatment of cancer. Curr Opin Immunol, 2008. 20(2): p. 241-6. 48. Petersen, R.P., et al., Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer, 2006. 107(12): p. 2866-72. 49. Oleinika, K., et al., Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol, 2013. 171(1): p. 36-45. 50. Cao, X., et al., Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity, 2007. 27(4): p. 635-46. 51. Sojka, D.K., A. Hughson, and D.J. Fowell, CTLA-4 is required by CD4+CD25+ Treg to control CD4+ T-cell lymphopenia-induced proliferation. Eur J Immunol, 2009. 39(6): p. 1544-51. 52. Jain, N., et al., Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A, 2010. 107(4): p. 1524-8. 53. Dubois, M., et al., A Colorimetric Method for the Determination of Sugars. Nature, 1951. 168: p. 167. 54. Wang, C.L., et al., Activation of antitumor immune responses by Ganoderma formosanum polysaccharides in tumor-bearing mice. Appl Microbiol Biotechnol, 2014. 98(22): p. 9389-98. 55. Dart, A., Cell genesis. Nat Rev Cancer, 2018. 18(6): p. 339-339. 56. Zhu, J., et al., Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat Commun, 2017. 8(1): p. 1404. 57. Zhao, M., et al., MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma. Mol Immunol, 2007. 44(11): p. 2923-32. 58. Haabeth, O.A.W., et al., Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun, 2011. 2: p. 240. 59. Kim, H.J. and H. Cantor, CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res, 2014. 2(2): p. 91-8. 60. Yang, L., et al., Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 2004. 6(4): p. 409-21. 61. Bronte, V., et al., Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun, 2016. 7: p. 12150. 62. Ostrand-Rosenberg, S., et al., Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol, 2012. 22(4): p. 275-281. 63. Wu, J. and L.L. Lanier, Natural killer cells and cancer. Adv Cancer Res, 2003. 90: p. 127-56. 64. Santoni, M., et al., Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother, 2013. 62(12): p. 1757-68. 65. Tracey, K.J. and A. Cerami, Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med, 1994. 45: p. 491-503. 66. Kohase, M., et al., Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell, 1986. 45(5): p. 659-66. 67. Alleva, D.G., C.J. Burger, and K.D. Elgert, Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol, 1994. 153(4): p. 1674-86. 68. Rosenberg, S.A., P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 1986. 233(4770): p. 1318-21. 69. Nencioni, A. and P. Brossart, Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells, 2004. 22(4): p. 501-13. 70. Rosenberg, S.A., J.C. Yang, and N.P. Restifo, Cancer immunotherapy: moving beyond current vaccines. Nat Med, 2004. 10(9): p. 909-15. 71. Xu, Z., et al., Ganoderma lucidum Polysaccharides: Immunomodulation and Potential Anti-Tumor Activities. Am J Chin Med, 2011. 39(01): p. 15-27. 72. Chen, Y., et al., Purification, composition analysis and antioxidant activity of a polysaccharide from the fruiting bodies of Ganoderma atrum. Food Chem, 2008. 107(1): p. 231-241. 73. Lee, S.Y. and H.M. Rhee, Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull (Tokyo), 1990. 38(5): p. 1359-64. 74. Liu, G.T., et al., [Some pharmacological actions of Ganoderma lucidum and G. japonicum (FR) Llyod on mouse liver (author's transl)]. Yao Xue Xue Bao, 1979. 14(5): p. 284-7. 75. Van Cutsem, E. and J. Arends, The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs, 2005. 9: p. S51-S63. 76. Cao, Z., et al., Antitumor and immunomodulatory effects of low-dose 5-FU on hepatoma 22 tumor-bearing mice. Oncol Lett, Vol. 7. 2014. 1260-1264. 77. Peter, M.E., et al., The role of CD95 and CD95 ligand in cancer. Cell Death Differ, 2015. 22(4): p. 549-59. 78. Mitra, R., S. Singh, and A. Khar, Antitumour immune responses. Expert Rev Mol Med, Vol. 5. 2003. 1-19. 79. Zhao, Q., et al., IFN-γ mediates graft-versus-breast cancer effects via enhancing cytotoxic T lymphocyte activity. Exp Ther Med, 2014. 8(2): p. 347-54. 80. Wu, J. and L.L. Lanier, Natural Killer Cells and Cancer, in Advances in Cancer Research. 2003, Academic Press. p. 127-156. 81. Wang, J., et al., 5-Fluorouracil targets thymidylate synthase in the selective suppression of TH17 cell differentiation. Oncotarget, 2016. 7(15): p. 19312-26. 82. Diaz-Montero, C.M., et al., Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother, 2009. 58(1): p. 49-59. 83. Gabrilovich, D.I. and S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 2009. 9(3): p. 162-74. 84. Vatner, R.E. and S.C. Formenti, Myeloid-Derived Cells in Tumors: Effects of Radiation. Semin Radiat Oncol, 2015. 25(1): p. 18-27. 85. Ugel, S., et al., Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest, 2015. 125(9): p. 3365-76. 86. Wu, H., et al., Polysaccharide from Lentinus edodes Inhibits the Immunosuppressive Function of Myeloid-Derived Suppressor Cells. PLOS ONE, 2012. 7(12): p. e51751. 87. Melero, I., et al., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer, 2015. 15(8): p. 457-72. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70471 | - |
dc.description.abstract | 台灣紫芝 (Ganoderma formosanum) 為台灣特有的靈芝品種。本實驗室利用液態深層發酵培養來取得胞外靈芝多醣,並且經過膠體過濾法進行純化,得到三個主要分劃PS-F1、PS-F2、PS-F3。本實驗室先前研究已經證實PS-F2對於已形成C26腫瘤的小鼠具有抗癌效果。本篇研究主要探討當PS-F2結合化療藥物5-fluorouracil (5-FU)是否對於抗癌效果有協同性的加乘。研究結果顯示口服PS-F2對於已形成C26腫瘤的小鼠便已有抑制腫瘤的效果,且PS-F2合併5-FU對於抑制腫瘤的生長有加乘性的效果。在脾臟中,單獨給予PS-F2或5-FU可顯著增加胞殺性T細胞,而合併治療組有更佳卓越的效果。另一方面,多核型骨髓衍生抑制細胞和調節型T細胞再單獨給予的組別就已有顯著性的下降,而合併治療組則有更顯著抑制效果。在浸潤淋巴結中,合併治療組胞殺性T細胞、輔助T細胞、自然殺手細胞則有較明顯上升的現象,另一方面在單獨治療組調節型T細胞比例皆有下降的情形,而合併治療組則有更進一步的下降。腫瘤微環境中,合併治療組其胞殺性T細胞有顯著性的上升,並且多核型骨髓衍生抑制細胞、調節型T細胞腫瘤相關巨噬細胞則有顯著性的下降。另外在單核型骨髓衍生抑制細胞上,我們也發現到給予PS-F2可促進其往巨噬細胞方向成熟,在腫瘤組織中,也偵測到TNF-α、IFN-β、IL-1β、IL-12和iNOS等促發炎相關基因表現有上升的趨勢,而抑制發炎arginase-1基因表現則有下降的趨勢。綜合上述結果,我們的實驗證明PS-F2不但可以活化體內的胞殺性T細胞並削弱免疫抑制型的細胞,而在合併治療上有加乘性的效果,因此PS-F2具有作為免疫療法藥物或者化療藥物佐劑的潛力。 | zh_TW |
dc.description.abstract | Ganoderma formosanum is a native species of Ganoderma isolated in Taiwan. We have used submerged mycelial culture to produce G. formosanum polysaccharides, and three polysaccharide fractions (PS-F1, PS-F2 and PS-F3) were purified by gel filtration chromatography. Our previous study showed that PS-F2 had antitumor effect in C26 colorectal tumor-bearing mice. In this study, we investigated whether combined treatment with PS-F2 and the chemotherapeutic agent 5-fluorouracil (5-FU) had a synergistic effect against C26 tumor growth in mice. Our data showed that PS-F2 treatment alone by oral gavage could suppress the growth of established tumor, and combined treatment with PS-F2 and 5-FU could further suppress tumor growth synergistically. In the spleen, PS-F2 and 5-FU monotherapies significantly enhanced the population of cytotoxic T lymphocytes (CTL), which was further augmented by the combined treatment. Conversely, the accumulation of immunosuppressive polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and regulatory T (Treg) cells were significantly reduced by PS-F2 and 5-FU monotherapies, and the effect was further augmented in the combination therapy. In the draining lymph nodes, the combination therapy also resulted in significant increases in interferon (IFN)-γ-producing CD4+ and CD8+ T cells. In the tumor microenvironment, combination therapy of PS-F2 and 5-FU significantly increased the CTL population and reduced the accumulation of PMN-MDSCs, Treg cells and tumor associated macrophages (TAMs). The combined therapy also promoted the maturation of monocytic myeloid-derived suppressor cells (M-MDSCs) in the spleen and the tumor. In addition, the combined treatment induced the expression of proinflammatory genes TNF-α, IFN-β, IL-1β, IL-12 and iNOS, and reduced the expression of arginase-1. Overall, our data demonstrate that of PS-F2 exerts its antitumor function by activating CTLs while downregulating immunosuppressive cells, and these effects can be further enhanced when PS-F2 is administered in combination with 5-FU, indicating that PS-F2 has the potential to be used in adjuvant immunotherapy alone or in combination with chemotherapy for the treatment of cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T04:28:55Z (GMT). No. of bitstreams: 1 ntu-107-R05b43025-1.pdf: 5099383 bytes, checksum: fdf522764980a9a6407bb1272ec3885b (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 目錄
中文摘要..........................................................I Abstract .........................................................II 縮寫表............................................................IV 目錄..............................................................VI 表目錄............................................................IX 圖目錄............................................................X 一、緒論...........................................................1 1. 靈芝簡介.....................................................1 2. 靈芝多醣體...................................................2 3. 腫瘤治療.....................................................2 4. 腫瘤微環境...................................................3 4.1 骨髓衍生抑制型細胞.........................................4 4.2 腫瘤相關巨噬細胞...........................................5 4.3 調節型T細胞........................................... ...5 二、研究動機.......................................................7 三、材料與方法.....................................................8 1. 實驗動物、細胞株和菌株.......................................8 2. 培養基配置...................................................8 3. 台灣紫芝培養.................................................9 4. 台灣紫芝胞外多醣PS-F2之回收與純化...........................9 5. 測定醣濃度..................................................10 6. PS-F2結合化療藥物5-FU之抗腫瘤活性評估......................10 7. 脾臟細胞製備................................................11 8. 浸潤淋巴結細胞製備..........................................11 9. 腫瘤細胞製備...............................................11 10. 細胞外染...................................................12 11. 細胞內染...................................................13 12. 腫瘤組織RNA的萃取並轉cDNA..............................14 13. Real-time Quantitative PCR (QPCR).............................15 14. 統計與繪圖軟體之分析.......................................15 四、實驗結果.....................................................16 1.靈芝胞外多醣體PS-F2合併化療藥物5-FU對於已形成腫瘤之抗腫瘤效果.16 2. PS-F2合併5-FU治療對於肝腎指數以及飲食的影響................17 3. PS-F2合併5-FU治療對於脾臟effector Th1細胞的影響..............17 4. PS-F2合併5-FU治療對於脾臟effector CTLs的影響..................17 5. PS-F2合併5-FU治療對於脾臟MDSCs的影響.....................18 6. PS-F2合併5-FU治療對於脾臟M-MDSC成熟與分化的影響.........18 7. PS-F2合併5-FU治療對於脾臟調節型T細胞的影響................19 8. PS-F2合併5-FU治療對於脾臟NK cells的影響....................19 9. PS-F2合併5-FU治療對於浸潤淋巴結effector Th1細胞的影響.......20 10. PS-F2合併5-FU治療對於浸潤淋巴結effector CTLs的影響.........20 11. PS-F2合併5-FU治療對於浸潤淋巴結調節型T細胞的影響.........20 12. PS-F2合併5-FU治療對於浸潤淋巴NK cells的影響................20 13. PS-F2合併5-FU治療對於腫瘤組織effector CTLs細胞的影響........20 14. PS-F2合併5-FU治療對於腫瘤MDSCs的影響.....................21 15. PS-F2合併5-FU治療對於腫瘤M-MDSC成熟與分化的影響.........21 16. PS-F2合併5-FU治療對於腫瘤調節型T細胞的影響................22 17. PS-F2合併5-FU治療對於腫瘤相關巨噬細胞 (TAM) 的影響.........22 18. PS-F2合併5-FU治療對於已生成腫瘤小鼠之生存曲線. .............22 20. PS-F2合併5-FU治療對於腫瘤組織發炎相關因子的影響............22 五、討論..........................................................24 六、圖表..........................................................27 七、參考文獻......................................................56 | |
dc.language.iso | zh-TW | |
dc.title | 台灣紫芝多醣體合併化療藥物之抗腫瘤效果 | zh_TW |
dc.title | Combination antitumor therapy with Ganoderma formosanum polysaccharides and chemotherapy | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 周子賓(Tze-Bin Chou) | |
dc.contributor.oralexamcommittee | 陳念榮(Nien-Jung Chen),江皓森(Hao-Sen Chiang) | |
dc.subject.keyword | 台灣紫芝,多醣體,免疫治療,骨髓衍生抑制細胞,T細胞,腫瘤相關巨噬細胞, | zh_TW |
dc.subject.keyword | Ganoderma formosanum,immunotherapy,extracellular polysaccharide,MDSCs,T cells,TAMs, | en |
dc.relation.page | 61 | |
dc.identifier.doi | 10.6342/NTU201802985 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-13 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 分子與細胞生物學研究所 | zh_TW |
顯示於系所單位: | 分子與細胞生物學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 4.98 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。